Document is current
Any future updates will be listed below
-
Authors
Seo, Caroline
Horodniceanu, Erica
Shah, Rachel
Goldstein, Grace
Ray, David
Bennett, Bonita
Phan, Alexandria
McCarrier, Kelly
-
Funding
Funding for this research was provided by:
Ipsen Biopharmaceuticals
- License Information
-
More Information
Article History
Received: 11 August 2021
Accepted: 7 April 2022
First Online: 27 April 2022
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki, the Belmont Report, and the Nuremberg Code. The study protocol was reviewed and deemed exempt from institutional review board (IRB) oversight by Advarra IRB (Columbia, MD).
: Written informed consent was obtained from all participants included in the study.
: All participants included in the study provided informed consent to the publishing of their de-identified study data.
: R.S. and K.M. are full-time employees of Pharmerit—an OPEN Health Company. C.S. and E.H. were full-time employees of Pharmerit—an OPEN Health Company at the time of the study. G.G. is a full-time employee of the Carcinoid Cancer Foundation, which has received grants from Advanced Applications, Ipsen, Lexicon, and Novartis. D.R. was a full-time employee and shareholder of Ipsen Biopharmaceuticals at the time of the study. B.B. declares no competing interests. A.P. reports speaker bureau, present at Ipsen and Lexicon.
